🔎 Trials Near Me

Почетна › Карцином на јајниците › Луизијана

Клинички испитувања за Карцином на јајниците во Луизијана

19 студии за Карцином на јајниците бараат учесници на локации во Луизијана.

Градови во Луизијана

Официјален текст на студијата (англиски)

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  • Louisiana State University HSC - NO Cancer Center, New Orleans
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 5.10.2026 · NCT06915025

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • University Medical Center New Orleans, New Orleans
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT07001748

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Ochsner Medical Center Jefferson, New Orleans
Се регрутираФаза 2
Сите возрасти · Сите полови · Ажурирано 5.10.2026 · NCT05564377

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Ochsner Clinic Foundation, New Orleans
Се регрутираНабљудувачка студија
Возраст 18 и постари · Жени · Ажурирано 29.9.2026 · NCT05051722

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • Women'S Cancer Care /ID# 276469, Covington
  • University Medical Center New Orleans /ID# 274755, New Orleans
  • Trials 365 /ID# 274310, Shreveport
Се регрутираФаза 2
Возраст 18 и постари · Жени · Ажурирано 29.9.2026 · NCT06890338

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Ochsner Clinic Foundation, New Orleans
  • Trials 365, Shreveport
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07213804

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  • Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440, Baton Rouge
Се регрутираФаза 2
Возраст 18 и постари · Жени · Ажурирано 22.9.2026 · NCT07059845

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • Women's Cancer Care ( Site 0018), Covington
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 17.9.2026 · NCT07318558

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Women'S Cancer Care, Covington
  • Trials365, Llc, Shreveport
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 15.9.2026 · NCT07214779

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Trials365, Llc, Shreveport
Се регрутираФаза 2
Возраст од 18 до 99 · Жени · Ажурирано 15.9.2026 · NCT07023627

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Tulane Cancer Center, New Orleans
  • Christus Highland/ Boniol, Shreveport
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT05059444

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  • Women's Cancer Care ( Site 0067), Covington
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 3.9.2026 · NCT06824467

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • West Jefferson Medical Center, Marrero
  • Louisiana State University Health Science Center, New Orleans
  • University Medical Center New Orleans, New Orleans
  • и уште 1
Се регрутира
Возраст од 35 до 50 · Жени · Ажурирано 7.8.2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • LSU Health Baton Rouge-North Clinic, Baton Rouge
  • Our Lady of the Lake Physician Group, Baton Rouge
  • Our Lady of The Lake, Baton Rouge
  • и уште 8
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 7.8.2026 · NCT06580314

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Our Lady of the Lake, Baton Rouge
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 30.7.2026 · NCT04657068

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • Louisiana State University Health Sciences Center, New Orleans
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 7.7.2026 · NCT05768139

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Trials365 LLC, Shreveport
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 2.7.2026 · NCT06819007

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

  • LSU Health New Orleans, New Orleans
  • University Medical Center New Orleans, New Orleans
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 16.4.2026 · NCT05659381

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, New Orleans
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 28.10.2025 · NCT03452774

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.